Emcure Pharmaceuticals Limited (BOM:544210)

India flag India · Delayed Price · Currency is INR
1,404.25
+11.35 (0.81%)
At close: Dec 4, 2025
2.13%
Market Cap 264.67B
Revenue (ttm) 84.49B
Net Income (ttm) 7.93B
Shares Out n/a
EPS (ttm) 41.87
PE Ratio 33.37
Forward PE 25.89
Dividend 3.00 (0.22%)
Ex-Dividend Date Aug 14, 2025
Volume 5,985
Average Volume 286,580
Open 1,393.65
Previous Close 1,392.90
Day's Range 1,382.10 - 1,429.70
52-Week Range 890.00 - 1,524.85
Beta n/a
RSI 52.34
Earnings Date Nov 11, 2025

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the develop... [Read more]

Industry Pharmaceutical Preparations
Founded 1981
Employees 6,731
Stock Exchange Bombay Stock Exchange
Ticker Symbol 544210
Full Company Profile

Financial Performance

In 2024, Emcure Pharmaceuticals's revenue was 78.96 billion, an increase of 18.59% compared to the previous year's 66.58 billion. Earnings were 6.81 billion, an increase of 36.76%.

Financial Statements

News

There is no news available yet.